1. Vascular Complications and Bleeding After Transfemoral TAVR With Surgical Versus Percutaneous Approach: A Contemporary Prospective Study.
- Author
-
Dardaillon, Annick Astié, Akodad, Mariama, Huet, Fabien, Meunier, Pierre Alain, Gandet, Thomas, Macia, Jean-Christophe, Schmutz, Laurent, Targosz, Frederic, Roubille, François, Steinecker, Matthieu, Lattuca, Benoit, Robert, Pierre, Berdeu, Jean-Michel, Cayla, Guillaume, Leclercq, Florence, and Iosseliani, David G.
- Subjects
- *
HEART valve prosthesis implantation , *PERIPHERAL vascular diseases , *ARTERIAL catheterization , *UNIVERSITY research , *LONGITUDINAL method - Abstract
Background: Percutaneous (PC) access has become the first‐line strategy for transfemoral (TF) transcatheter aortic valve replacement (TAVR), but surgical cutdown (SC) may be required in selected and usually challenging cases. We aimed to compare the efficacy and safety of SC versus echo‐guided PC approach in TF TAVR. Methods: Between November 2019 and December 2020, all patients undergoing TF TAVR were included in a prospective study. The choice of PC or SC strategy was left at operators' discretion, according to predictable access site difficulties. The primary endpoint included all vascular complications (VCs) and all bleeding at 1‐month follow‐up according to Valve Academic Research Consortium‐2 criteria. Results: Among 225 patients, 166 (73.8%) and 59 (26.2%) underwent PC or SC approach, respectively. Median age was 82 years, EuroSCORE 2 was higher (p = 0.02), and peripheral arterial disease (p < 0.001) was more common in the SC group. Femoral access was successful in 100% in the SC group vs 97.6% in the PC group (p = 0.2). The primary endpoint was reached in 32 patients (14.2%), 5 (8.4%) in the SC group and 27 (16.2%) in the PC group (p = 0.1) with low incidence of major VC in both groups (1.7% vs 3% in the SC and PC groups respectively, p = 0.6). Conclusion: Despite a higher risk profile of patients in the SC group, SC and PC approaches appear safe and effective in TF TAVR, with a high success rate. SC may be considered when vascular access is anticipated as complex, but this strategy might be confirmed in a randomized study. Trial Registration: ClinicalTrials.gov identifier: NCT03865043 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF